# OnCo record cln-049 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cln-049/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cln-049" ;
  schema:name "CLN-049"@en ;
  schema:description "CLN-049 is an experimental bispecific T cell engager from Cullinan Therapeutics, in phase 2 trials for relapsed or refractory acute myeloid leukaemia, myelodysplastic syndrome and newly diagnosed acute myeloid leukaemia."@en ;
  schema:url <https://onco.cc/drugs/cln-049/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://cullinantherapeutics.com/pipeline/>, <https://cullinantherapeutics.com/pipeline/>, <https://cullinantherapeutics.com/pipeline/>, <https://clinicaltrials.gov/api/v2/studies/NCT05143996>, <https://clinicaltrials.gov/search?intr=CLN-049> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Bispecific T cell engager" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/> ;
  onco:targets <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/cullinan-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct05143996/>, <https://onco.cc/trials/nct07722767/> .